Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials

Cayce Nawaf; Alexander Shiang; Pradeep S. Chauhan; Aadel A. Chaudhuri; Gautum Agarwal; Zachary L. Smith

doi:10.1016/j.tranon.2023.101763

Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials

Cayce Nawaf, Alexander Shiang, Pradeep S. Chauhan, Aadel A. Chaudhuri, Gautum Agarwal, Zachary L. Smith

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed method for non-invasive monitoring has been to utilize a “liquid biopsy.” Liquid biopsy has been proposed as a non-invasive method of testing biomarkers in bodily fluids in order to detect and survey cancer. The liquid biopsy could be utilized to obtain information regarding circulating tumor cells, circulating cell-free tumor DNA, circulating cell-free tumor RNA, and more. It is currently being investigated to help guide adjuvant therapy and improve oncological outcomes. We highlight an array of exciting past and ongoing clinical trials regarding ctDNA and adjuvant therapy in regard to urothelial carcinoma which we believe to be amongst the leaders in the field.

Original language	English
Article number	101763
Journal	Translational Oncology
Volume	37
DOIs	https://doi.org/10.1016/j.tranon.2023.101763
State	Published - Nov 2023

Keywords

Biomarkers
Circulating tumor DNA
Clinical trials
Genitourinary
Immunotherapies

Access to Document

10.1016/j.tranon.2023.101763

Cite this

@article{d334e87a69ce4938b7e65cc550740bc3,

title = "Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials",

abstract = "Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed method for non-invasive monitoring has been to utilize a “liquid biopsy.” Liquid biopsy has been proposed as a non-invasive method of testing biomarkers in bodily fluids in order to detect and survey cancer. The liquid biopsy could be utilized to obtain information regarding circulating tumor cells, circulating cell-free tumor DNA, circulating cell-free tumor RNA, and more. It is currently being investigated to help guide adjuvant therapy and improve oncological outcomes. We highlight an array of exciting past and ongoing clinical trials regarding ctDNA and adjuvant therapy in regard to urothelial carcinoma which we believe to be amongst the leaders in the field.",

keywords = "Biomarkers, Circulating tumor DNA, Clinical trials, Genitourinary, Immunotherapies",

author = "Cayce Nawaf and Alexander Shiang and Chauhan, {Pradeep S.} and Chaudhuri, {Aadel A.} and Gautum Agarwal and Smith, {Zachary L.}",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = nov,

doi = "10.1016/j.tranon.2023.101763",

language = "English",

volume = "37",

journal = "Translational Oncology",

issn = "1936-5233",

}

TY - JOUR

T1 - Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials

AU - Nawaf, Cayce

AU - Shiang, Alexander

AU - Chauhan, Pradeep S.

AU - Chaudhuri, Aadel A.

AU - Agarwal, Gautum

AU - Smith, Zachary L.

PY - 2023/11

Y1 - 2023/11

N2 - Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed method for non-invasive monitoring has been to utilize a “liquid biopsy.” Liquid biopsy has been proposed as a non-invasive method of testing biomarkers in bodily fluids in order to detect and survey cancer. The liquid biopsy could be utilized to obtain information regarding circulating tumor cells, circulating cell-free tumor DNA, circulating cell-free tumor RNA, and more. It is currently being investigated to help guide adjuvant therapy and improve oncological outcomes. We highlight an array of exciting past and ongoing clinical trials regarding ctDNA and adjuvant therapy in regard to urothelial carcinoma which we believe to be amongst the leaders in the field.

AB - Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed method for non-invasive monitoring has been to utilize a “liquid biopsy.” Liquid biopsy has been proposed as a non-invasive method of testing biomarkers in bodily fluids in order to detect and survey cancer. The liquid biopsy could be utilized to obtain information regarding circulating tumor cells, circulating cell-free tumor DNA, circulating cell-free tumor RNA, and more. It is currently being investigated to help guide adjuvant therapy and improve oncological outcomes. We highlight an array of exciting past and ongoing clinical trials regarding ctDNA and adjuvant therapy in regard to urothelial carcinoma which we believe to be amongst the leaders in the field.

KW - Biomarkers

KW - Circulating tumor DNA

KW - Clinical trials

KW - Genitourinary

KW - Immunotherapies

UR - http://www.scopus.com/inward/record.url?scp=85169007800&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2023.101763

DO - 10.1016/j.tranon.2023.101763

M3 - Article

C2 - 37657155

AN - SCOPUS:85169007800

SN - 1936-5233

VL - 37

JO - Translational Oncology

JF - Translational Oncology

M1 - 101763

ER -

Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this